Skip to main content
UniHealth

Doctor search

Meghan Mullen Dickman, MD

Dermatology · Stanford

NPI 1356617260

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
14
3 carriers
Offices
5

Offices

5 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

14 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dickman’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

14 of 14 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A126496 · Current

Licensed to practise in California · since 2013 · expires 2027-03-31 · University of California San Francisco School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$291,511

Medicare paid this office $291,511 for 1,013 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)423$59,343$104
Short return visit (20+ min)461$39,137$72
Destruction of precancer skin growth, 1 growth552$33,234$50
Biopsy of related skin growth, first growth219$22,274$86
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm65$18,868$286
See all 22 services
Every Original Medicare service billed
Return visit (30+ min)423$59,343$104
Short return visit (20+ min)461$39,137$72
Destruction of precancer skin growth, 1 growth552$33,234$50
Biopsy of related skin growth, first growth219$22,274$86
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm65$18,868$286
Destruction of skin growth, 1-14 growths152$18,414$110
Destruction of precancer skin growth, 2-14 growths449$16,226$7
New patient visit (45+ min)82$11,663$142
New patient visit (30+ min)123$11,479$93
Destruction of precancer skin growth, 15 or more growths49$9,285$150
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)12$5,425None
Punch biopsy, first skin growth43$4,457$104
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm33$4,067$123
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm27$3,753$139
Biopsy of related skin growth, each additional growth42$3,188$51
Application of light to destroy precancer skin growth13$1,975$152
Injection into skin growth, 1-7 growths14$1,132$47
New patient visit (15+ min)15$840$56
Short return visit15$679$42
Punch biopsy, each additional skin growth11$551$46
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's12$193$15
Injection, triamcinolone acetonide, not otherwise specified, 10 mg16$35None

Procedures Medicare counted

Procedure volume Medicare published
Melanoma (skin cancer) excision41More than 84% of doctors who do this
Removal of skin lesions1278More than 95% of doctors who do this
Removal or shaving of skin growth43More than 78% of doctors who do this
Skin biopsy289More than 90% of doctors who do this

Who their Medicare patients are

1,013 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 10% · Women 57% · Also on Medicaid 9% · Health risk score 1.05. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 69% · Chronic kidney disease 22% · Diabetes 21% · Coronary heart disease 21% · Cancer 20% · Atrial fibrillation 15% · Depression 13% · Heart failure 11% · COPD 11% · Stroke 7% · Dementia 4%.

The office billed $1,393,511, Medicare allowed $405,306 and paid $291,511; for 5,809 services of 47 kinds; $5,460 of it was for drugs given in the office and $286,051 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241,0135,809751.05$1,393,511$291,511
20239205,600741.08$1,267,066$289,091
20227595,084731.08$1,137,208$255,849
20218315,004731.13$1,117,662$258,286
20207744,203741.27$861,602$176,348
20197233,706731.31$742,962$164,295
20184591,980731.19$386,847$88,624
20173571,531731.14$259,266$63,045
201682182711.13$23,471$7,354

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 22 services

Original Medicare services billed in 2023
Return visit (30+ min)338$51,374$111
Short return visit (20+ min)436$42,883$78
Destruction of precancer skin growth, 1 growth467$31,313$52
Biopsy of related skin growth, first growth189$22,340$98
Destruction of precancer skin growth, 2-14 growths387$17,366$7
Destruction of precancer skin growth, 15 or more growths70$16,334$163
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm45$14,792$308
New patient visit (30+ min)146$13,336$91
New patient visit (45+ min)94$12,907$137
Destruction of skin growth, 1-14 growths84$10,141$111
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)17$8,014None
Punch biopsy, first skin growth40$4,914$123
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm28$3,999$125
Biopsy of related skin growth, each additional growth46$3,708$52
Application of light to destroy precancer skin growth18$3,141$157
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm14$1,921$137
New patient visit (15+ min)31$1,662$54
Short return visit25$1,158$46
Telehealth originating site facility fee47$1,026$21
Punch biopsy, each additional skin growth14$921$61
Injection into skin growth, 1-7 growths14$757$45
Injection, triamcinolone acetonide, not otherwise specified, 10 mg22$27None

2022: 21 services

Original Medicare services billed in 2022
Return visit (30+ min)280$42,809$106
Short return visit (20+ min)380$37,406$76
Destruction of precancer skin growth, 1 growth407$27,997$50
Biopsy of related skin growth, first growth212$22,745$90
Destruction of precancer skin growth, 2-14 growths322$15,572$7
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)22$12,421None
Destruction of precancer skin growth, 15 or more growths54$11,904$153
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm36$10,908$295
New patient visit (30+ min)123$10,491$85
New patient visit (45+ min)75$9,350$125
Destruction of skin growth, 1-14 growths64$7,594$104
Punch biopsy, first skin growth51$6,309$117
Biopsy of related skin growth, each additional growth61$4,276$52
Application of light to destroy precancer skin growth22$4,246$157
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm21$2,573$123
Short return visit46$2,232$49
New patient visit (15+ min)39$2,086$53
Punch biopsy, each additional skin growth20$1,398$61
Injection into skin growth, 1-7 growths24$1,275$43
Telehealth originating site facility fee52$1,022$17
Injection, triamcinolone acetonide, not otherwise specified, 10 mg28$33None

2021: 21 services

Original Medicare services billed in 2021
Return visit (30+ min)286$40,967$110
Short return visit (20+ min)377$35,653$76
Destruction of precancer skin growth, 1 growth403$24,941$47
Biopsy of related skin growth, first growth186$18,554$87
New patient visit (30+ min)187$17,668$94
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)20$13,231None
New patient visit (45+ min)94$13,019$139
Destruction of precancer skin growth, 2-14 growths319$12,468$6
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm35$11,219$312
Destruction of skin growth, 1-14 growths88$9,942$97
Punch biopsy, first skin growth61$6,995$109
Destruction of precancer skin growth, 15 or more growths37$6,775$144
Application of light to destroy precancer skin growth19$3,327$145
Biopsy of related skin growth, each additional growth47$2,946$49
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm22$2,656$121
New patient visit (15+ min)40$2,433$61
Short return visit29$1,445$48
Telehealth originating site facility fee65$1,362$19
Punch biopsy, each additional skin growth17$959$56
Injection into skin growth, 1-7 growths18$932$37
Injection, triamcinolone acetonide, not otherwise specified, 10 mg17$23None

2020: 20 services

Original Medicare services billed in 2020
Return visit (30+ min)310$37,102$88
Short return visit (20+ min)311$21,576$58
Destruction of precancer skin growth, 1 growth315$17,113$43
New patient visit (30+ min)144$12,794$89
Destruction of skin growth, 1-14 growths121$11,506$89
Biopsy of related skin growth, first growth133$9,930$69
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)11$8,936None
New patient visit (15+ min)148$8,377$57
Destruction of precancer skin growth, 2-14 growths246$8,125$5
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm22$6,474$294
Destruction of precancer skin growth, 15 or more growths35$5,206$130
Punch biopsy, first skin growth42$4,182$97
Telehealth originating site facility fee116$2,898$21
Biopsy of related skin growth, each additional growth38$2,524$49
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm16$2,223$117
Telephone medical discussion with physician, 11-20 minutes20$1,269$58
Application of light to destroy precancer skin growth11$1,086$99
Injection into skin growth, 1-7 growths17$860$41
Punch biopsy, each additional skin growth14$820$51
Injection, triamcinolone acetonide, not otherwise specified, 10 mg14$27None

2019: 14 services

Original Medicare services billed in 2019
Return visit (30+ min)253$33,145$87
Short return visit (20+ min)272$19,750$58
Destruction of precancer skin growth, 1 growth288$18,696$47
New patient visit (30+ min)187$16,177$87
Destruction of skin growth, 1-14 growths99$10,225$87
New patient visit (15+ min)176$9,963$57
Biopsy of related skin growth, first growth129$9,443$68
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm23$6,800$296
Destruction of precancer skin growth, 2-14 growths222$6,485$4
Punch biopsy, first skin growth52$5,442$103
Destruction of precancer skin growth, 15 or more growths23$3,548$127
Biopsy of related skin growth, each additional growth32$1,867$44
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm15$1,779$119
Punch biopsy, each additional skin growth19$1,099$52

2018: 9 services

Original Medicare services billed in 2018
New patient visit (30+ min)175$15,671$90
Short return visit (20+ min)174$12,170$60
Return visit (30+ min)99$11,640$90
Destruction of precancer skin growth, 1 growth183$11,140$48
Destruction of skin growth, 1-14 growths93$9,695$96
Biopsy of single growth of skin and/or tissue95$7,639$73
New patient visit (15+ min)105$6,505$62
Destruction of precancer skin growth, 2-14 growths147$3,206$4
Biopsy of each additional growth of skin and/or tissue29$1,250$29

2017: 9 services

Original Medicare services billed in 2017
New patient visit (30+ min)149$11,247$75
Short return visit (20+ min)128$8,885$54
Destruction of precancer skin growth, 1 growth120$6,752$45
New patient visit (15+ min)118$6,565$56
Destruction of skin growth, 1-14 growths55$4,886$81
Biopsy of single growth of skin and/or tissue73$4,685$58
Return visit (30+ min)40$4,552$86
Destruction of precancer skin growth, 2-14 growths90$1,601$4
Biopsy of each additional growth of skin and/or tissue16$468$28

2016: 5 services

Original Medicare services billed in 2016
New patient visit (30+ min)30$1,985$66
Return visit (30+ min)20$1,542$70
Short return visit (20+ min)26$1,231$46
Destruction of precancer skin growth, 1 growth15$663$41
Biopsy of single growth of skin and/or tissue16$594$37

Medicaid work

$307 in 2020

Medicaid paid $307 for 18 billed services this clinician did in 2020, up to 18 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2020
Telehealth originating site facility fee18$307
Medicaid work by year
202018118$307

Drugs they prescribed that Part D paid

$1,865,113

Pharmacies billed $1,865,113 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,651) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

1,380 generic and 271 brand-name prescriptions · $1,865,113 in drug cost · 19 antibiotic prescriptions to 16 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Skyrizi27$531,576$19,688
Dupixent68$285,671$4,201
Humira(Cf)32$268,770$8,399
Cosentyx (2 Syringes)14$162,433$11,602
Dupixent23$101,028$4,393
See all 29 drugs
Every Part D drug this clinician prescribed
Skyrizi27$531,576$19,688
Dupixent68$285,671$4,201
Humira(Cf)32$268,770$8,399
Cosentyx (2 Syringes)14$162,433$11,602
Dupixent23$101,028$4,393
Otezla13$62,678$4,821
Jublia17$16,263$957
Fluorouracil95$7,021$74
Clobetasol Propionate82$5,729$70
Tacrolimus45$5,486$122
Ketoconazole276$4,281$16
Calcipotriene22$3,867$176
Triamcinolone Acetonide173$3,145$18
Fluocinonide78$2,637$34
Metronidazole27$1,389$51
Nystatin40$1,095$27
Hydroxyzine42$921$22
Desonide15$911$61
Minoxidil96$894$9
Valacyclovir31$773$25
Betamethasone Dipropionate16$757$47
Clindamycin Phosphate31$686$22
Ciclopirox18$592$33
Hydrocortisone113$542$5
Betamethasone Diprop Augmented11$515$47
Fluocinolone Acetonide13$461$35
Finasteride22$263$12
Spironolactone11$176$16
Mupirocin16$143$9

Year by year

Part D prescribing by year
20241,6515350% (0)16%$1,865,113
20231,3144190% (0)None$1,529,897
20221,2344010% (0)15%$1,408,114
20211,3394300% (0)14%$1,122,499
20201,259405None17%$1,094,967
20191,0263240% (0)None$650,438
20185202110% (0)None$177,540
2017408146None16%$121,557
201682450% (0)18%$10,931
201521None0% (0)None$3,629
201416NoneNoneNone$1,831

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 27 drugs

Part D drugs prescribed in 2023
Humira(Cf)38$349,497$9,197
Cosentyx Sensoready11$162,702$14,791
Dupixent35$131,410$3,755
Dupixent29$110,324$3,804
Fluorouracil84$7,161$85
Tacrolimus36$5,289$147
Clobetasol Propionate52$4,954$95
Ketoconazole216$4,057$19
Fluocinonide62$3,583$58
Triamcinolone Acetonide159$2,234$14
Desonide20$1,241$62
Betamethasone Dipropionate15$1,008$67
Clindamycin Phosphate22$994$45
Hydroxyzine22$813$37
Valacyclovir14$615$44
Doxycycline Hyclate32$553$17
Minoxidil50$528$11
Nystatin18$471$26
Hydrocortisone94$466$5
Clotrimazole13$455$35
Ciclopirox12$390$33
Dexamethasone11$280$25
Gabapentin19$268$14
Finasteride25$222$9
Spironolactone15$143$10
Prednisone12$101$8
Mupirocin11$93$8

2022: 24 drugs

Part D drugs prescribed in 2022
Humira(Cf)37$346,029$9,352
Stelara12$219,701$18,308
Humira18$116,746$6,486
Dupixent27$95,933$3,553
Cosentyx (2 Syringes)11$75,222$6,838
Fluorouracil73$6,733$92
Ketoconazole230$5,177$23
Fluocinonide71$4,328$61
Clobetasol Propionate41$3,608$88
Tacrolimus23$3,131$136
Triamcinolone Acetonide147$1,827$12
Betamethasone Dipropionate16$1,316$82
Doxycycline Hyclate22$729$33
Fluocinolone Acetonide11$673$61
Ciclopirox12$645$54
Hydrocortisone109$620$6
Nystatin11$484$44
Finasteride36$338$9
Valacyclovir14$318$23
Gabapentin20$239$12
Hydroxyzine17$224$13
Minoxidil29$222$8
Mupirocin20$216$11
Spironolactone15$124$8

2021: 31 drugs

Part D drugs prescribed in 2021
Humira(Cf)42$388,350$9,246
Humira28$181,017$6,465
Dupixent26$86,887$3,342
Otezla18$65,922$3,662
Fluorouracil71$6,204$87
Ketoconazole202$4,846$24
Fluocinonide89$4,596$52
Clobetasol Propionate45$4,307$96
Triamcinolone Acetonide202$2,762$14
Calcipotriene11$1,884$171
Tacrolimus13$1,607$124
Metronidazole15$1,239$83
Desonide13$1,186$91
Nystatin18$1,106$61
Imiquimod16$1,037$65
Betamethasone Dipropionate15$1,022$68
Ciclopirox21$826$39
Fluocinolone Acetonide11$786$71
Hydrocortisone118$737$6
Betamethasone Diprop Augmented11$718$65
Doxycycline Hyclate16$666$42
Methotrexate16$561$35
Hydroxychloroquine Sulfate12$477$40
Clindamycin Phosphate11$420$38
Nystatin-Triamcinolone18$412$23
Gabapentin18$401$22
Mupirocin28$316$11
Finasteride19$251$13
Hydroxyzine32$246$8
Spironolactone12$215$18
Acyclovir12$40$3

2020: 32 drugs

Part D drugs prescribed in 2020
Stelara16$320,147$20,009
Humira(Cf)26$257,448$9,902
Humira25$142,649$5,706
Enbrel21$120,015$5,715
Dupixent18$58,378$3,243
Otezla15$53,375$3,558
Jublia11$9,135$830
Fluorouracil55$6,112$111
Fluocinonide89$5,662$64
Ketoconazole158$3,543$22
Calcipotriene16$3,492$218
Triamcinolone Acetonide192$2,767$14
Clobetasol Propionate38$2,479$65
Betamethasone Dipropionate21$1,555$74
Fluocinolone Acetonide18$1,537$85
Nystatin11$1,285$117
Doxycycline Hyclate15$1,157$77
Clindamycin Phosphate17$1,006$59
Fluocinolone Acetonide12$1,003$84
Imiquimod12$944$79
Hydrocortisone131$867$7
Clotrimazole11$773$70
Dexamethasone16$680$43
Methotrexate19$583$31
Ciclopirox21$529$25
Nystop17$450$26
Gabapentin12$320$27
Spironolactone13$288$22
Finasteride17$205$12
Hydroxyzine23$190$8
Mupirocin20$164$8
Prednisone23$128$6

2019: 24 drugs

Part D drugs prescribed in 2019
Stelara14$241,196$17,228
Humira23$126,248$5,489
Enbrel22$118,738$5,397
Fluorouracil42$4,896$117
Clobetasol Propionate44$4,035$92
Calcipotriene16$3,788$237
Fluocinonide53$3,287$62
Triamcinolone Acetonide154$3,109$20
Ketoconazole122$2,834$23
Doxycycline Hyclate32$2,577$81
Nystatin22$1,344$61
Imiquimod11$1,104$100
Clindamycin Phosphate20$932$47
Fluocinolone Acetonide12$836$70
Dexamethasone20$734$37
Hydrocortisone95$530$6
Ciclopirox16$494$31
Mupirocin38$394$10
Valacyclovir13$345$27
Prednisone34$293$9
Clotrimazole11$234$21
Gabapentin19$195$10
Finasteride11$117$11
Hydroxyzine17$99$6

2018: 16 drugs

Part D drugs prescribed in 2018
Humira12$62,442$5,204
Acitretin11$14,234$1,294
Fluocinolone Acetonide22$2,258$103
Fluocinonide30$2,110$70
Ketoconazole69$1,936$28
Fluorouracil19$1,904$100
Clobetasol Propionate11$1,560$142
Triamcinolone Acetonide73$1,159$16
Clindamycin Phosphate21$1,088$52
Metronidazole18$766$43
Ciclopirox13$583$45
Nystatin14$464$33
Hydrocortisone54$424$8
Doxycycline Hyclate12$297$25
Mupirocin19$130$7
Prednisone17$88$5

2017: 10 drugs

Part D drugs prescribed in 2017
Clobetasol Propionate16$2,825$177
Metronidazole23$2,579$112
Fluorouracil18$2,080$116
Fluocinonide40$2,076$52
Clindamycin Phosphate16$1,116$70
Ketoconazole43$1,051$24
Doxycycline Hyclate14$746$53
Triamcinolone Acetonide47$736$16
Hydrocortisone38$320$8
Mupirocin20$180$9

2016: 2 drugs

Part D drugs prescribed in 2016
Triamcinolone Acetonide13$310$24
Ketoconazole12$235$20

Money from drug and device companies

$47 in 2024

Industry payments by year
202413None$47
202323None$77
202211None$34
201922None$149

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
STRATA Skin SciencesXtrac$47
3 payments
  • Meals for Xtrac · 2024-03-07 · $18
  • Meals for Xtrac · 2024-03-05 · $6
  • Meals for Xtrac · 2024-02-21 · $23
See all 3 published payments
Every published payment
STRATA Skin SciencesMeals · 2024-03-07Xtrac$18
STRATA Skin SciencesMeals · 2024-03-05Xtrac$6
STRATA Skin SciencesMeals · 2024-02-21Xtrac$23
See earlier years (2023, 2022, 2019)

2023: $77

Payments by company in 2023
Inari MedicalFlowtriever Catheter, S$62
2 payments
  • Meals for Flowtriever Catheter, S · 2023-11-07 · $30
  • Meals for Flowtriever Catheter, S · 2023-09-29 · $32
PfizerCibinqo$15
1 payment
  • Education for Cibinqo · 2023-04-12 · $15

2022: $34

Payments by company in 2022
STRATA Skin SciencesXtrac$34
1 payment
  • Meals for Xtrac · 2022-09-19 · $34

2019: $149

Payments by company in 2019
UcbNone$134
1 payment
  • Meals · 2019-03-01 · $134
DUSA PharmaceuticalsLevulan Kerastick$15
1 payment
  • Meals for Levulan Kerastick · 2019-08-07 · $15

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1356617260
Licence
CA A126496California A126496: Current · expires 2027-03-31
Trained
University of California, San Francisco School of Medicine, 2012
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
450 Broadway St # B, Redwood City, CA, 94063
NPI first listed
2012-03-25
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 1133 E Stanley Blvd Ste 111, Livermore, CA, 94550 · 450 Broadway St # B, Redwood City, CA, 94063